Crinetics Pharmaceuticals, Inc. (CRNX)
NASDAQ: CRNX · Real-Time Price · USD
46.67
-0.75 (-1.58%)
At close: Dec 5, 2025, 4:00 PM EST
46.60
-0.07 (-0.15%)
After-hours: Dec 5, 2025, 5:48 PM EST
Crinetics Pharmaceuticals Revenue
Crinetics Pharmaceuticals had revenue of $143.00K in the quarter ending September 30, 2025. This brings the company's revenue in the last twelve months to $1.54M, up 47.74% year-over-year. In the year 2024, Crinetics Pharmaceuticals had annual revenue of $1.04M, down -74.11%.
Revenue (ttm)
$1.54M
Revenue Growth
+47.74%
P/S Ratio
2,885.08
Revenue / Employee
$3,513
Employees
437
Market Cap
4.43B
Revenue Chart
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
CRNX News
- 3 days ago - Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors - GlobeNewsWire
- 9 days ago - Biotech Fund Dumps $12.3 Million in Crinetics Stock as Shares Remain 19% Lower on the Year - The Motley Fool
- 15 days ago - Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome - GlobeNewsWire
- 25 days ago - Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Why Crinetics Pharmaceuticals Stock Was Sliding on Friday - The Motley Fool
- 4 weeks ago - Crinetics Pharmaceuticals, Inc. (CRNX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Crinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 6 weeks ago - Crinetics to Highlight Neuroendocrine Tumor Research Progress at the 2025 North American Neuroendocrine Tumor Society Annual Meeting - GlobeNewsWire